Next-generation Xpert® MTB/RIF Ultra assay recommended by WHO

The World Health Organization (WHO) recently recommended the use in all settings of a next-generation Xpert® MTB/RIF assay (called Xpert® MTB/RIF Ultra) as a replacement for the current Xpert MTB/RIF® cartridge.
The Ultra cartridge, that has been developed by Cepheid (Sunnyvale, USA), showed significantly better performance (increased sensitivity) compared to the current Xpert® MTB/RIF cartridge for the detection of Mycobacterium tuberculosis in specimens with low numbers of bacilli, especially in smear-negative, culture-positive specimens (such as those from persons with HIV co-infection), in paediatric specimens and in extra-pulmonary specimens (notably cerebrospinal fluid). The accuracy in detection of rifampicin resistance was also better although not enough data were available to conclusively confirm this.
“Innovations in technology and the strong science behind it have brought significant breakthroughs in TB diagnosis over the last 10 years” said Dr Mario Raviglione, Director of the WHO Global TB Programme. “Achieving the targets in the WHO End TB Strategy necessitates urgent scale-up of these innovations at all levels and in all settings for early and rapid diagnosis of TB and rifampicin resistance in all persons with signs or symptoms of TB.”
Source :      2017/5/3 09:32

خانه چاپ ارسال به دوستان نسخه متنی کوچک کردن متن بزرگ کردن متن دانلود خروجی پی دی اف خروجی میکروسافت ورد
0/10 (تعداد آرا 0 نفر )
Copyright © 2011 AASM. All Rights Reserved.